Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8UPO3)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase (CDK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[2]
Flavopiridol	DMKSUOI	Acute myeloid leukaemia	2A60	Phase 2	[3]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[4]
PF-06873600	DMRZHV6	Breast cancer	2C60-2C65	Phase 1	[4]
Purine derivative 4	DMYD5SQ	N. A.	N. A.	Patented	[1]
Indole-based analog 12	DM1CNRH	N. A.	N. A.	Patented	[1]
PMID26161698-Compound-10	DMXVCHZ	N. A.	N. A.	Patented	[1]
BS-194	DMLXFHD	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Targeting CDC7-related kinase (CDC7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-863233	DM5HUY8	Haematological malignancy	2B33.Y	Phase 1/2	[6]
TAK-931	DM1ALY9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
PMID19115845C89S	DMB9F2L	Discovery agent	N.A.	Investigative	[7]
PMID20873740C18	DMVHR3Z	Discovery agent	N.A.	Investigative	[8]
PMID24793884C74	DMFSJQC	Discovery agent	N.A.	Investigative	[9]
PMID24793884C77	DMZENGX	Discovery agent	N.A.	Investigative	[9]
PHA-767491	DM4H7D5	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2	Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
3	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176).
6	Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.
7	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
8	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
9	Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
10	Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64.